Realm Therapeutics, Inc.

39 articles about Realm Therapeutics, Inc.

• ESSA Announces that the Scheme of Arrangement with Realm Therapeutics has become Effective

  7/31/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce that, further to the announcement made on July 30, 2019, the scheme of arrangement under Part 26 of the U.K. Companies Act 2006 has become effective and ESSA has acquired all of the issued and outstanding shares of Realm Therapeutics plc.

• ESSA Announces Court Sanction of the Scheme of Arrangement with Realm Therapeutics

  7/30/2019

  ESSA Pharma Inc. is pleased to announce that, further to the announcement made on July 8, 2019, the High Court of Justice in England and Wales has today sanctioned the scheme of arrangement under Part 26 of the U.K. Companies Act 2006, pursuant to which ESSA will acquire all of the issued and outstanding shares of Realm Therapeutics plc.

• ESSA Provides an Update to the Acquisition of Realm Therapeutics

  6/26/2019

  ESSA Pharma Inc., a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer provides an update, further to the announcement made on May 16, 2019 announcing the acquisition of Realm Therapeutics plc by ESSA pursuant to a scheme of arrangement under Part 26 of the U.K. Companies Act 2006.

• Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

  5/16/2019

  ESSA Pharma Inc. announced that it has entered into a definitive agreement with Realm Therapeutics plc setting forth the terms of an acquisition whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction.

• Realm Therapeutics Announces 2018 Annual Report Available and Form 20-F Filing

  4/10/2019

  Realm Therapeutics plc announces that its 2018 Annual Report is now available on the Company's website, www.realmtx.com, and will be posted to those shareholders who have not elected to receive the document electronically.

• Realm Therapeutics Announces Receipt of Nasdaq Listing Determination and Requests Hearing

  4/5/2019

  Realm Therapeutics plc announced that the Company received written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that, based upon the Company's recent Assets Disposal, the Staff believes the Company is a "shell company" and, as such, the continued listing of American Depositary Shares representing the Company's ordinary shares on Nasdaq is no longer warranted.

• Realm Therapeutics Announces Completion of Assets Disposal

  3/29/2019

  Realm Therapeutics plc announces the completion of its previously announced Assets Disposal representing certain assets, which comprise the Vashe® wound care royalty stream, an FDA 510-cleared anti-itch hydrogel, which was formerly marketed as Aurstat™, HOCI related equipment, intellectual property, program records, and certain assigned contracts and intellectual property licenses.

• Realm Therapeutics Announces Cancellation of AIM Listing

  3/26/2019

  Realm Therapeutics plc announced on March 15, 2019 that the listing of the Company's Ordinary Shares on AIM will cease and cancellation will be effective from 7:00 a.m. on March 27, 2019.

• Realm Therapeutics Announces Result of General Meeting

  3/15/2019

  Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, announces that at the Company's general meeting, held today in connection with the proposed Assets Disposal to Urgo, U.S. Inc., proposed adoption of the Investing Policy and proposed AIM Delisting,

• Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company"), Update on Strategic Review, Proposed Assets Disposal, Proposed Adoption of Investing Policy, Proposed AIM Delisting and Notice of General Meeting

  2/15/2019

  Realm Therapeutics plc, a biopharmaceutical company with a proprietary technology platform of stabilized high concentration HOCl, provides an update on its previously announced strategic review.

• Realm Therapeutics Provides Update on Strategic Review

  11/29/2018

  Realm Therapeutics plc today provides an update on timing of the ongoing formal sale process as part of the previously announced strategic review.

• 

  Realm Therapeutics Slashes Staff and Explores Potential Sale as the Company Conducts a Strategic ...

  9/17/2018

  Following a trial failure with its atopic dermatitis treatment, Malvern, Penn.-based Realm Therapeutics has opted to discontinue all of its drug development programs and is considering a potential sale of the company.

• Realm Therapeutics Provides Corporate Update and Hires Advisor to Support Strategic Review including Formal Sale Process

  9/17/2018

  Realm Therapeutics plc today provides a corporate update following the August 14, 2018 announcement of top-line results of the Company's Phase 2 trial of PR022 in Atopic Dermatitis

• Realm Therapeutics Reports Top-line Data from Phase 2 Trial of PR022 in Atopic Dermatitis and First Half 2018 Financial Results

  8/14/2018

  In a randomized, double-blind, vehicle controlled, Phase 2 clinical trial of 122 patients, PR022 showed no difference from vehicle in the primary endpoint of percent change in Eczema Area Severity Index (EASI) versus baseline.

• 

  Realm Craters As Another Phase II Trial Fails to Reach Endpoints

  8/14/2018

  Shares of Realm Therapeutics have plunged more than 50 percent this morning after the company announced its Phase II atopic dermatitis drug failed to distinguish itself from the control arm in the trial.

• Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

  8/8/2018

  Realm Therapeutics plc announces that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14, 2018 at 4:15 p.m. ET at the Parker New York.

• Realm Therapeutics to Report First Half 2018 Financial Results

  8/7/2018

  Realm's management team will host a conference call and audio webcast at 9:00 a.m. ET / 2:00 p.m. BST on Tuesday, August 14, 2018 to discuss the financial results and recent operational highlights.

• Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis

  7/10/2018

  Realm Therapeutics plc announces the publication of a pre-clinical study demonstrating comparable activity between PR022, Realm's proprietary topical gel formulation of high concentration hypochlorous acid (HOCl), and tofacitinib, a topical Janus kinase (JAK) inhibitor

• Realm Therapeutics Announces Results of 2018 Annual General Meeting

  6/14/2018

  Proxy figures will be displayed shortly on the Company's website

• Realm Therapeutics to Present at June 2018 Investor Conferences

  5/31/2018

  Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company will participate in several investor conferences in June.